



<https://ijrps.com>

ISSN: 0975-7538

Research Article

Formulation and *in vitro* comparative evaluation of orodispersible tablets of Granisetron hydrochloride

Srinivasa DS, Narayana Charyulu R, Prabhakara Prabhu*, Nithish Kumar, Marina Koland, Satyanarayana DS, Srilakshmi D

Department of Pharmaceutics, Nitte University, Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences, Mangalore – 575 018, Karnataka, India

ABSTRACT

In the present work, an attempt has been made to formulate oral dispersible tablets of granisetron HCl by three different methods. Conventional tableting procedure was followed for the preparation of tablets. Nine batches of tablets were prepared and evaluated for general appearance and physical parameters, drug content, *in vitro* disintegration, *in vitro* dispersion, *in vitro* drug release, kinetic and stability studies. Formulations prepared by superdisintegrants addition method emerged as the best formulations, as they showed rapid *in vitro* disintegration time, *in vitro* dispersion time and drug release at the end of 5 min, apart from taste and excellent mouth feel compared to formulations prepared by sublimation and effervescent methods. It was concluded that oral dispersible tablets of granisetron HCl can be successfully formulated and will be used as a novel drug dosage form for pediatrics and geriatrics with improved patient compliance.

Keywords: Granisetron HCl; Orodispersible Tablets; Superdisintegrants; Effervescent; Sublimation

INTRODUCTION

Recent developments in technology have presented viable dosage alternatives for patients who have difficulty in swallowing the tablets or liquids. Traditional tablets and capsules administered with an 8-oz. glass of water may be inconvenient or impractical for some patients. Dysphagia or chewing solid dosage forms, which is a common problem of all age groups, particularly pediatrics and geriatrics, because of physiological changes associated with these groups (Aurora J & Pathak V., 2005). Dysphagia is also associated with the number of medical conditions, including stroke, Parkinson's disease, AIDS, head and neck radiation therapy and other neurological disorders, including cerebral palsy. Other categories that experience problems using conventional oral dosage forms include are mentally ill, uncooperative and nauseated patients, those with motion sickness, sudden episodes of allergic attack or coughing (Bogner RH & Wilkosz MF., 2005), sometimes, it may be difficult to swallow the conventional products due to unavailability of water (Kaushik D *et al.*, 2004). These problems cause the need for delivering drugs to patients efficiently, and with few side effects have prompted pharmaceutical companies to

engage in the development of new drug delivery systems. Oral dispersible tablets (ODT) are perfect fit for all this kind of patients. ODT is those solid dosage forms when put on the tongue, disintegrate or dissolve instantaneously, releasing the drug, within a few seconds without the need of water. When this type of tablet is placed into the mouth, the saliva will serve to rapidly disintegrate the tablet. The faster the drug into solution, quicker the absorption and onset of clinical effect. ODT release drug in the mouth for absorption through local oral mucosal tissues and through pregastric (i.e., oral cavity, pharynx and oesophagus), gastric (i.e., stomach) and post gastric (i.e., small and large intestine) (Pfister WR & Ghosh TK., 2005) In such cases, the bioavailability of some drugs may be increased due to absorption of drugs in oral cavity and also due to pregastric absorption of saliva containing dispersed drugs that pass down significantly greater than those observed from conventional dosage forms (Panigrahi D *et al.*, 2005). ODT are also known as 'fast dissolving', 'mouth dissolving', 'rapid-dissolve', 'quick disintegrating', 'orally disintegrating', 'rapimelt', 'fast melts', 'melt-in-mouth', 'quick dissolving', 'porous tablets', 'EFVDAS' or 'Effervescent Drug Absorption System (Sreenivas SA *et al.*, 2005). ODT technology has been approved by United States Pharmacopoeia (USP), Centre for Drug Evaluation and Research (CDER). USFDA defined ODT as "A solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue". Recently, European Pharmacopoeia also

* Corresponding Author

Email: prabhuprabhu@rediffmail.com

Contact: +91-824-2203991 Fax: +91-824-2203992

Received on: 07-02-2012

Revised on: 20-03-2012

Accepted on: 21-03-2012

adopted the term "Oro Dispersible Tablet" (Guidance for Industry).

Cancer chemotherapy causes a lot of adverse effects, of which nausea and vomiting are prime one. This can be clearly seen with model anticancer drug cisplatin, which is first line drug in many types of cancers. Hence anti emetic drugs like ondansetron, granisetron are administered one hour prior to the administration of anticancer drug (Thomson Micromedex Healthcare., 2005). However, this becomes a major patient non compliance in the case of children, elderly and bed ridden patients for whom swallowing tablets causes inconvenience (Shu T *et al.*, 2002). Among the dosage forms developed to facilitate ease of medication. The rapid disintegrating tablet (RDT) is one of the most

widely employed commercial products (Koizumi K *et al.*, 1997). Hence, present investigation is an attempt to improve patient compliance by formulating anti-emetic drug granisetron hydrochloride in the form of oral dispersible tablets.

MATERIALS AND METHODS

Materials

Granisetron hydrochloride was obtained as a gift sample from Sun Pharmaceuticals, Baroda. Croscarmellose sodium, Crospovidone, Sodium bicarbonate, Citric acid, Ammonium bicarbonates were procured from Ozone international, Mumbai. All other chemicals used were of analytical grade.

Table 1: Formulations of oro dispersible tablets

Ingredients (mg/tab)	Formulation Code								
	SD1	SD2	SD3	EV1	EV2	EV3	SL1	SL2	SL3
Granisetron HCl	2	2	2	2	2	2	2	2	2
Croscarmellose sodium	12.5 (5%)		12.5 (5%)	-	-	-	-	-	-
Crospovidone	7.5 (3%)	12.5 (5%)		-	-	-	-	-	-
Sodium starch glycolate	-	7.5 (3%)	7.5 (3%)	-	-	-	-	-	-
Avicel pH102	134.25	134.25	134.25	50	50	50	-	-	-
Mannitol (30%)	75	75	75	129.75	129.75	129.75	75	75	75
Sodium Bicarbonate	-	-	-	-	20 (8%)	25 (10%)	-	-	-
Citric acid (Anhydrous)	-	-	-	20 (8%)	15 (6%)	25 (10%)	-	-	-
Ammonium Bicarbonate	-	-	-	-	-	-	150 (60%)	100 (40%)	50 (20%)
Aerosil (2%)	5	5	5	-	-	-	-	-	-
Starch (4%)	-	-	-	10	10	10	10	10	10
Sodium saccharin (0.8%)	-	-	-	2	2	2	2	2	2
Purified Talc (2%)	5	5	5	5	5	5	5	5	5
Magnesium stearate (1%)	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
Strawberry flavor (1.5%)	3.75	3.75	3.75	3.75	3.75	3.75	3.75	3.75	3.75

Table 2: Evaluation of orodispersible tablets

Formulation code	Hardness* \pm SD (kg/cm ²)	Disintegration Time (sec) \pm SD	Dispersion Time (sec) \pm SD	Wetting Time(sec) \pm SD
SD1	2.5 \pm 0.14	18.32 \pm 0.67	21.50 \pm 1.5	25.00 \pm 3.28
SD2	2.87 \pm 0.22	22.12 \pm 2.16	26.00 \pm 2.0	32.00 \pm 3.00
SD3	2.22 \pm 0.12	16.82 \pm 1.16	18.00 \pm 1.0	22.14 \pm 2.50
EV1	3.20 \pm 0.15	36.00 \pm 3.0	42.64 \pm 2.44	50.16 \pm 2.33
EV2	2.89 \pm 0.14	44.80 \pm 2.85	47.5 \pm 2.94	52.00 \pm 3.00
EV3	3.15 \pm 0.25	41.26 \pm 2.73	46.31 \pm 3.51	42.00 \pm 1.89
SL1	2.4 \pm 0.07	26.00 \pm 2.0	30.06 \pm 2.41	34.16 \pm 2.73
SL2	2.54 \pm 0.08	31.51 \pm 1.35	34.12 \pm 3.21	36.83 \pm 3.21
SL3	2.70 \pm 0.21	33.32 \pm 2.5	38.24 \pm 3.18	40.00 \pm 1.68

Methods

Formulation of orodispersible Tablets

In the present study, orodispersible tablets of granisetron HCl were prepared by direct compression technique.

Preparation of ODT of Granisetron HCl using Superdisintegrant addition Method

The superdisintegrants used were croscarmellose sodium, crospovidone and sodium starch glycolate. All the ingredients were passed through a sieve #40 and kept in a hot air oven at 80 °C to make anhydrous and accurately weighed. The drug, superdisintegrants, Avicel pH 102, mannitol sweetener, aerosol, and flavor were triturated well in a mortar to mix them properly. Magnesium stearate and talc were then passed through a sieve #80, mixed and blended with the initial mixture. The mixed blend of drug and excipients was compressed using rotary punch MINIPRESS II (Karnavathi) tableting machine to produce tablet weighing 250 mg having a diameter of 8 mm. Following above procedure, three batches of ODT of granisetron HCl in a different ratio were prepared (S. Banker, and G. R. Anderson., 1987).

Preparation of ODT of Granisetron HCl by Effervescent Formulation Approach

Sodium bicarbonate and citric acid (anhydrous) were used as effervescent agents. All the ingredients were passed through a sieve #40 and kept in a hot air oven at 80 °C to make anhydrous and accurately weighed. The drug, effervescent agents, Avicel pH 102, mannitol, starch, sweetener, and flavor were triturated well in a mortar to mix them properly. Magnesium stearate and talc were then passed through a sieve #80, mixed and blended with the initial mixture. The mixed blend of drug and excipients was compressed using rotary punch MINIPRESS II (Karnavathi) tableting machine to produce tablet weighing 250 mg having a diameter of 8 mm following above procedure, three batches of ODT of granisetron HCl in a different ratio of Sodium bicarbonate and citric acid were prepared.

Preparation of ODT of Granisetron HCl by Sublimation Method

Ammonium bicarbonate was used as a sublimable component. Accurately weighed quantities of the drug sublimable component, mannitol and sodium saccharin were mixed and passed through a sieve #40. All the ingredients were grounded in a glass mortar to get a uniform mixture. Then the remaining excipients were added, thoroughly triturated and compressed using the rotary punch MINIPRESS II (Karnavathi) tableting machine to produce a tablet weighing 250 mg having a diameter of 8 mm. The prepared tablets were packed in an aluminum foil pouch. Following above procedure, three batches of ODT of granisetron HCl, in a different ratio of ammonium bicarbonate were prepared.

Evaluation of oro dispersible Tablets

Hardness and Friability

Hardness and Friability of tablets were determined as per IP by using Monsanto hardness tester and Roche Friabilator respectively (British Pharmacopoeia., 1988).

Wetting time

A piece of tissue paper folded twice was placed in a small petridish containing 6 ml of simulated saliva pH (phosphate buffer pH 6.8). A tablet was put on the paper and the time required for complete wetting was measured. Six trials for each batch were performed and an average time for wetting with standard deviation was recorded (Wade A & Weller PT., 1984).

Surface pH

The surface pH of the tablets was determined in order to investigate the possibility of any side effects due to change in pH *in vivo* since an acidic or alkaline pH may cause irritation to the buccal mucosa. A combined glass electrode was used for the purpose. The tablets were allowed to swell by keeping them in contact with 1 ml of simulated saliva for 2 h and pH was noted by bringing the electrode in contact with the surface of the formulations (Wade A & Weller PT, 1984) and allowing it to equilibrate for 1 min.

Drug content estimation

As per USP, twenty tablets were weighed and powdered. A quantity of powder equivalent to 10 mg of granisetron HCl was accurately weighed, transferred into a 100 ml volumetric flask and dissolved in 0.1 N HCl. After shaking for 10 min, the volume was made up to 100 ml with 0.1 N HCl. The above solution (1 ml) was taken and diluted to 10 ml and was analyzed spectrophotometrically at 307 nm and percentage of granisetron HCl was determined (Wade A & Weller PT., 1984).

Weight variation test

Uniformity of weight test as described in the IP was followed. Using this procedure weight variation range of all batches of formulations were determined and recorded (Liebermann HA., 1990).

Uniformity of drug content

One tablet was powdered and transferred to a 100 ml volumetric flask and dissolved in 0.1N HCl. The volume was made up to 100 ml. From this 1 ml was pipetted out and diluted to 10 ml with 0.1N HCl in 10 ml volumetric flask. The absorbance was measured spectrophotometrically at 307 nm. The test was carried out individually for five tablets from each formulation (Wade A & Weller PT., 1984).

In vitro Disintegration time

In vitro disintegration time was determined using a disintegration test apparatus (Thermonik). A tablet was placed in each of the six tubes of the apparatus, and




Figure 1: In vitro drug release profile

one disc was added to each tube. The time in seconds taken for complete disintegration of the tablet with no palpable mass remaining in the apparatus was measured in seconds (Wade A & Weller PT., 1984)

In vitro Dispersion Time

A tablet was put into a measuring cylinder containing 6 ml of phosphate buffer pH 6.8 (simulated saliva pH). Time required for complete dispersion of a tablet was recorded. This test was performed for six tablets from each batch and average time taken for dispersion with standard deviation was recorded (Kuchekar BS *et al.*, 2003; Ozeki T *et al.*, 2003).

In vitro drug release studies

In vitro drug release studies were carried out by using USP XXIII dissolution apparatus II (Paddle type) [Electro lab (TDT-06T) Tablet Dissolution Tester] at 50 rpm. The drug release profile was studied in 900 ml of hydrochloric acid buffer at pH 1.2 by maintaining at 37 ± 0.5 °C. Aliquots of 10 ml of a dissolution medium were withdrawn at specific time intervals (1, 2, 3, 4 and 5 min), filtered and the amount of drug released was determined spectrophotometrically at 307 nm.

Stability Studies

Twenty tablets from each batch were selected at random and were packed in aluminum foil. Ten tablets from each batch were kept in a desiccator at room temperature, and the other 10 were kept at room temperature on a shelf (at RH 80%) for one month. The tablets were checked for physical appearance, hardness, weight difference, *in vitro* dispersion time and *in vitro* drug release profile. Then the results were compared with those obtained immediately after compression.

RESULTS AND DISCUSSION

All the ODT formulations by superdisintegrant addition method showed less *in vitro* disintegration time (< 23 sec) and *in vitro* dispersion time (< 26 sec). The formu-

lation containing croscarmellose sodium (5% w/w) formulation SD3 emerged to be the best. This is because of least hardness of 2.22 ± 0.12 Kg/cm and presence of croscarmellose sodium in higher concentration. Among the superdisintegrant formulations croscarmellose less disintegration & dispersion time because it will draw water & swell. Crospovidone will increase disintegration time. As a result crospovidone will increase the disintegration & dispersion time.

Among the effervescent formulations, EV1 showed least disintegration time & dispersion time and among the sublimation formulations SL1 showed least disintegration & dispersion time may be due to presence of sodium bicarbonate & ammonium bicarbonate.

As far as drug content, weight variation, friability tests are concerned formulation were within IP limits. The surface pH is concerned all the formulations remained within 6.5-7.5 pH. Hence, it was found to be compatible with the oral cavity pH (6.8).

Wetting time of tablets of all formulations reflected in the disintegration time & dispersion time (Table 2) and *in vitro* release profile (Fig 1).

Stability studies indicated that no significant variation was found as far as physical & in process parameters of formulations were concerned. Hence, the formulations were found to be stable and also no shift in λ_{max} was found.

CONCLUSION

The oral dispersible tablets of granisetron HCl were prepared by three different methods and among the methods employed superdisintegrant formulations was found to be better compared to other two methods like effervescent and sublimation formulations. Further, the formulation parameters reflected in the release of drug from the formulations. Hence, the methods employed to prepare the formulations of ODT found to be effective, and the formulations were found

to be better patient compliance, especially for pediatrics and geriatrics.

ACKNOWLEDGEMENT

The authors wish to acknowledge Nitte University, Mangalore (Karnataka) India, for providing the necessary facilities and financial support to carry out this project. Further, the authors are also grateful to Sun Pharmaceuticals Pvt Ltd, Baroda, Gujarat, for providing free sample of Granisetron HCl.

REFERENCES

- Aurora J, Pathak V, 2005. Oral disintegrating dosage forms: an overview. *Oral disintegrating technologies. Drug Del Tech*, 5(3), 1-5.
- Banker S, and Anderson GR. In Lachman L, Leon Liberman HA, and Kanig JL. (eds.), 1987. *The Theory and Practice of Industrial Pharmacy*, Ed. 3, Varghese Publishing House, Mumbai, p 293-345.
- Bogner RH, Wilkosz MF, 2005. Fast-dissolving tablets. *U. S. Pharmacist*. A Jobson Publication: p 1-5.
- British Pharmacopoeia, 1988. Vol I. Her Majesty's Stationary Office, London, UK;;36.
- Guidance for Industry 1: Orally disintegrating tablets. U. S. Food and Drug Administration. www.fda.gov/cder/Guidance/5909dft.htm#_Toc462221103
- Kaushik D, Dureja H, Saini TR, 2004. Mouth dissolving tablets: A Review. *Indian Drugs*, 41 (4), 187-193.
- Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M, 1997. New method for preparing high porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. *Int J Pharm*, 152, 127-131.
- Kuchekar BS, Atul CB, Mahajan HS, 2003. Mouth dissolving tablets: A novel delivery system. *Pharma Times*, 35, 7-9.
- Liebermann HA, Lachman L, Kanig JL, 1990. *The theory and practice of industrial pharmacy* 3rd ed. USA: Varghese Publishing house, p 253 -296.
- Ozeki T, Yasuzawa Y, Katsuyama H, Takashima Y, Kasai T, Eguchi T, et al, 2003. Design of rapidly disintegrating oral tablets using acid- treated yeast cell wall: a technical note. *AAPS Pharm SciTech*; 4(4), Article 70.
- Panigrahi D, Baghel S, Mishra B. Mouth dissolving tablets: An overview preparation techniques, evaluation and patented technologies. *J Pharma Res* 2005; 4 (3): 33-38.
- Patel MM, Patel DM, 2004. Effect of superdisintegrants on the dissolution rate of valdecoxib from tablets. *Int J Pharma Excip*, 3(3), 64-68.
- Pfister WR, Ghosh TK, 2005. Orally Disintegrating Tablets. *Pharmaceutical Technology*. Pharma tech, 1-11. www.pharmatech.com
- Shu T, Suzuki H, Hironaka K, Ito K, 2002. Studies of rapidly disintegrating tablets in oral cavity using co ground mixture of mannitol with crospovidone. *Chem Pharm Bull*, 50, 193-198.
- Sreenivas SA, Dandagi PM, Gadad AP, Godbole AM, Hiremath AP, Mastiholimath VS, Bhagvati ST, 2005. Oro dispersible tablet: New-fanged drug delivery system—A review. *Ind J Pharm Educ Res*, 39 (4), 177-181.
- Thomson Micromedex Healthcare, 2001. Ondansetron hydrochloride (systemic). In: *Drug Information for Health Care Professionals: USP DI*. Greenwood Village, CO: Micromedex Thomson Healthcare, 2248-2250.
- Wade A, Weller PT, 1994. In: *Handbook of Pharmaceutical Excipients*. 2nded. The American Pharmaceutical Association, Washington, DC, USA and The Pharmaceutical Press, UK;; p. 84-86, 123- 144, 280-295, 418-425, 462-465.